Skip to content
DataLookout
Menu

NCT06747923

SB17170 Phase 2 Trial in IPF Patients

StatusCompleted
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 22 words Show 7 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of May 30, 2026 to Jul 21, 2026
    • Enrollment target: estimated 30 to confirmed 32
    • Study completion date changed from estimate of Oct 31, 2026 to Jul 28, 2026
    • Secondary endpoints: details revised at 3 of 5 entries
    • Study description revised
    • Site details revised at 5 of 5 sites
  2. Minor Primary completion date: Apr 7, 2026 to May 30, 2026v7
  3. Minor Study description revisedv6
  4. Minor Start date: Dec 30, 2024 to Jan 27, 2025v5
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 5 of 5 sites
    v4
  6. Minor Study description shortened, about 3 wordsv2
  7. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Change from baseline in FVC (ml)
Timeframe: Week 12

Secondary (3)

Change from baseline in FVC (%)
Change from baseline in DLCO
Change from baseline in quality of life and symptoms

Arms and interventions

SB17170 of A mg, Single doseExperimental
SB17170 of B mg, Single doseExperimental
PlaceboPlacebo comparator

Drugs: SB17170, Placebo

Sites

5 sites in 1 country